First Manhattan’s Catalyst Pharmaceutical CPRX Stock Holding History

First Manhattan’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-250	Closed	-$3.98K	–	796
2024 Q1	$3.98K	Hold	250	–	–	﹤0.01%	1220
2023 Q4	$4.2K	Hold	250	–	–	﹤0.01%	1219
2023 Q3	$2.92K	Hold	250	–	–	﹤0.01%	1286
2023 Q2	$3.36K	Hold	250	–	–	﹤0.01%	1262
2023 Q1	$4.14K	Hold	250	–	–	﹤0.01%	1319
2022 Q4	$4.65K	Hold	250	–	–	﹤0.01%	1417
2022 Q3	$3K	Hold	250	–	–	﹤0.01%	1375
2022 Q2	$1K	Hold	250	–	–	﹤0.01%	1473
2022 Q1	$2K	Hold	250	–	–	﹤0.01%	1475
2021 Q4	$1K	Hold	250	–	–	﹤0.01%	1520
2021 Q3	$1K	Hold	250	–	–	﹤0.01%	1543
2021 Q2	$1K	Buy	+250	New	+$1.29K	﹤0.01%	1525

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

First Manhattan's CPRX Position: Q2 2024 in Review

First Manhattan sold out of Catalyst Pharmaceutical (CPRX) in Q2 2024, closing a stake of 250 shares — an estimated $3.98K sold.

First Manhattan first reported a position in CPRX in Q2 2021 and held it in 12 quarters. The position peaked at $4.65K in Q4 2022. 271 funds tracked by Wall St. Rank hold CPRX as of Q2 2024.

First Manhattan reported no remaining Catalyst Pharmaceutical position as of Q2 2024 after selling out during the quarter.
First Manhattan sold 250 Catalyst Pharmaceutical shares in Q2 2024, an estimated $3.98K.
First Manhattan first reported a position in Catalyst Pharmaceutical in Q2 2021 and held it in 12 quarters.
First Manhattan's Catalyst Pharmaceutical position peaked at $4.65K in Q4 2022.
271 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.